AMENDMENTS TO THE CLAIMS

This list of claims replaces the claims in the application.

Claims 1-53 (canceled)

54. (new) A compound having the structure I

a prodrug of the compound, a pharmaceutically acceptable salt of the compound, a stereoisomer of the compound, a tautomer of the compound, or a solvate of the compound

wherein the dashed lines in structure I represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,6-diene, 1,7-diene, 1,8-diene, 1,15-diene, 4,8-diene, 3,16-diene within the fused four-ring system.

55. (new). The compound of claim 1, wherein the fused ring system is a 1,6-diene.

56. (new) A compound having the structure II

a prodrug of the compound, a pharmaceutically acceptable salt of the compound, a stereoisomer of the compound, a tautomer of the compound, or a solvate of the compound

wherein the dashed lines in structure II represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,3-diene, or 1,5-diene within the fused four-ring system.

57. (new) The compound of claim 58, wherein the fused ring system is a 1,5-diene.

58. (new) A compound having the structure IIA

IIA

wherein,

X and Y are -O- or -S-;

Z is optionally substituted C2-C4 alkyl;

each R¹⁵ is independently H or C(O)-R¹⁵; wherein R¹⁵ is lower alkyl; and the dashed lines in structure IIA represent carbon-carbon double bonds or carbon-carbon single bonds contained within the fused four-ring system, such that the compound comprises a 1,3-diene, or 1,5-diene within the fused four-ring system.

59. (new) The compound of claim 58, wherein both R^{11} are -C(O)-CH₃; and the compound comprises a 1,5-diene within the fused four-ring system

60. (new) A compound having the structure:

61. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and at least one compound of claims 54 or claim 56.